Where can I learn more about this study?
You can find more information about this study on the websites listed below.
• www.clinicaltrials.gov Once you are on the website, type “NCT03463525”
into the search box and click “Search”.
• www.clinicaltrialsregister.eu. Once you are on the website, click “Home and Search”,
then type “2018-000262-10” in the search box and click “Search”
• www.AstraZenecaClinicalTrials.com Once you are on the website, type “D5160C00043”
into the search box, and click “Find a Study”.
Full Study Title: An Open-label Positron Emission Tomography (PET) Study to Determine Brain
Exposure of Osimertinib after Intravenous Microdose Administration of [11C] Osimertinib and
Therapeutic Oral Doses of Osimertinib to Patients with EGFR Mutated Non-Small Cell Lung
Cancer and Brain Metastases
AstraZeneca Protocol Number: D5160C00043
National Clinical Trials Number: NCT03463525
EudraCT Number: 2018-000262-10
AstraZeneca AB sponsored this study and has its headquarters at Södertälje, Sweden.
The phone number for the AstraZeneca Information Center is +1-877-240-9479.
Thank you!
Clinical study participants and their families belong to a large community of people who take
part in clinical research around the world. They help researchers answer important health
questions and find medical treatments for patients.
The Center for Information & Study on Clinical Research Participation (CISCRP) is a non-profit organization focused on
educating and informing the public about clinical research participation. CISCRP is not involved in recruiting participants
for clinical studies, nor is it involved in conducting clinical studies.
CISCRP | One Liberty Square, Suite 1100 • Boston, MA 02109 | 1-877-MED-HERO | www.ciscrp.org
Version 1.0_2021_10_06
8 | Clinical Study Results